Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17322682 | 0.93 | ALDH1A1 (0.38) | ALDH1A1LMNAKMT2AMAPTCA1 | |
| SCHEMBL17322684 | 0.92 | ALDH1A1 (0.38) | ALDH1A1LMNAKMT2AMAPTCA1 | |
| SCHEMBL17325863 | 0.88 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMAPTCA1 | |
| SCHEMBL20079589 | 0.82 | ALDH1A1 (0.40) | ALDH1A1LMNAKMT2AMAPTCA1 | |
| SCHEMBL21554140 | 0.80 | LMNA (0.42) | ALDH1A1LMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL20079622 | 0.78 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMAPTCA1 | |
| SCHEMBL13224653 | 0.78 | LMNA (0.45) | ALDH1A1LMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL15765285 | 0.77 | CA2 (0.36) | ALDH1A1LMNAKMT2AMAPTCA1 | |
| SCHEMBL13527700 | 0.74 | HDAC1 (0.42) | CA1CA2FOLH1 | |
| SCHEMBL10014305 | 0.74 | CA1 (0.35) | LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9950083-B2 | Polypeptide and imaging method | KYOTO UNIVERSITY (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20150352233-A1 | Polypeptide and Imaging Method | ARKRAY, INC. (JP) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352233-A1 | Polypeptide and Imaging Method | GLP1R, NGLY1, NPY1R | ALDH1A1 3779/4885LMNA 677/4885KMT2A 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.